ASX energy stock Amplitude Energy Ltd (ASX: AEL) has fallen significantly in 2026. 

It is an energy exploration and development company focused on conventional gas projects in southeast Australia. 

The company also has interests in oil and condensate-producing assets in the Cooper Basin.

Since the start of the year, its share price has fallen over 50%. 

However the team at Bell Potter have released a new report. The broker is now suggesting it could be set for a significant rebound following the company’s June quarter results. 

Softer demand, but position remains solid

According to Bell Potter, Amplitude Energy’s June 2026 quarter was broadly in line with expectations. 

Gas production at its main Orbost plant was slightly lower because the company intentionally reduced output as warmer weather and strong gas supply in eastern Australia weakened demand and spot prices. 

The average gas selling price also dipped slightly to the previous quarter. 

Despite these softer market conditions, the energy company still met its full-year production guidance. It ended the quarter in a healthy financial position with $138 million in cash and relatively low net debt of $37 million. 

Investors should also expect the company to provide production guidance for FY27 when it releases its full-year results in August.

Existing operations improve 

Bell Potter also noted that although the Orbost site was temporarily shut down for maintenance during the quarter, the work improved the plant’s efficiency and allowed it to achieve record production rates once it restarted. 

Amplitude Energy has also confirmed that its major growth project, the East Coast Supply Project (ECSP), remains on budget and on track to begin production in 2028. 

The final exploration well will be drilled soon, and importantly, Amplitude Energy says the entire project can be funded through its existing financing and cash flow, meaning it does not currently need to raise additional capital.

Upside in tact for this ASX energy stock 

Based on this guidance, Bell Potter has retained its buy recommendation on this ASX energy stock. 

It has also retained its price target of $2.50, which indicates almost 80% upside from current levels. 

AEL is a pure-play leverage to the southern east coast Australia gas market with the majority of its gas sales under stable contracted prices. The company’s flagship 100%-owned Gippsland Basin asset is now consistently operating near nameplate capacity (68TJ/day); debottlenecking could see incremental improvements.

AEL’s 50%-owned Otway Basin expansion is supported by existing gas discoveries and up to 24TJ/day net Gas Sales Agreements with EnergyAustralia and AGL Energy.

The post Why this ASX energy stock could be set to rise 80%: Expert appeared first on The Motley Fool Australia.

More reading

• Amplitude Energy shares could be set to soar 90%: Expert
• Are these oversold ASX shares too good to pass up?
• This ASX gas company could more than double in value: Broker

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

It has been a tough year for ASX utilities stock LGI Ltd (ASX: LGI). 

LGI designs and installs biogas extraction systems. It recovers biogas from landfills and converts it into renewable electricity and saleable environmental products.

It now sits close to 52-week lows after falling over 30% this year. 

Why has this ASX utilities stock fallen this year?

While the business has continued to announce new projects, the share price has retreated significantly from yearly highs. 

LGI’s share price has fallen in 2026 despite continued operational progress, with the decline largely driven by weaker sentiment rather than a deterioration in the business. 

After a strong rally in 2025, investors have now taken profits while the broader market has become less willing to pay high valuations for growth-focused small caps.

Uncertainty surrounding Australian carbon credit prices, which influence a portion of LGI’s earnings, has also weighed on investor confidence.

Some catalysts for LGI over the next 12–18 months include growth in renewable electricity generation from new projects, ACCU (carbon credit) prices and policy developments, operating margins as new facilities mature and continued contract wins with landfill operators.

What is Morgan’s latest guidance on this ASX utilities stock?

Yesterday, the team at Morgans provided an updated outlook on LGI. 

The broker said LGI’s FY26 growth update (via social media) highlighted five newly registered carbon sites, strong ACCU creation and in-line electricity generation (130 GWh, +33% yoy), which it expects to more than offset the delayed Mugga Lane battery commissioning (now FY27, previously 2H FY26). 

While we view FY26 as intact, weaker wholesale electricity and LGC prices have weighed on the medium-term earnings outlook, driving material EPS revisions (FY27 -25%, FY28 -38%) and a de-rating in the stock. Near-term earnings face ongoing headwinds from weaker commodity prices, and we expect FY27 to step back before growth resumes.

Over the medium term, we continue to view LGI positively given the material development pipeline ahead (~4x FY25) as the group scales and executes its meaningful battery rollout. BUY, A$3.10ps price target.

From current levels, this price target from Morgans indicates just over 17% potential upside.

Elsewhere, it appears experts view this ASX utilities stock as undervalued. 

Four analyst forecasts via TradingView have an average one year price target of $4.11 on LGI shares. 

This indicates more than 50% upside from current levels. 

The post Morgans just placed a fresh buy rating on this ASX utilities stock  appeared first on The Motley Fool Australia.

More reading

• How have CSL shares performed over 10 years?
• 3 ways to get from $100,000 to $500,000 in retirement savings
• 5 things to watch on the ASX 200 on Thursday
• Own ACDC, FANG, or SEMI ETF? Global X is paying your dividend today!
• 3 amazing ASX ETFs I’d buy this month

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended LGI Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) was once the ASX healthcare share many investors wished they had bought years earlier.

For a long time, it seemed almost unstoppable.

But the past few years have changed the story completely.

So, how have CSL shares actually performed over the last decade?

The 10-year return

CSL shares are trading around $121.75.

Ten years ago, they were changing hands at around $119.00.

That means the share price has risen by approximately 2% over the decade.

That is a positive return, but it is much weaker than many investors would expect from a company that was once viewed as one of the highest-quality growth shares on the ASX.

Dividends have helped. CSL has paid 20 dividends over that period, totalling approximately $30.57 per share.

If those dividends are added to the share price gain, the total return becomes better. A shareholder who bought at $119 would have collected around $33.32 per share in combined capital gains and dividends, before tax and ignoring reinvestment.

That works out to a total return of roughly 28%.

What went wrong?

The frustrating part is that CSL shares were once much higher.

The stock traded around $315 in 2021, and was still around that level as recently as 2024.

At that point, long-term shareholders were sitting on a much stronger return. Since then, the decline has been painful.

I think the market has lost confidence in CSL’s growth story.

The plasma business was disrupted by the pandemic, and higher collection and manufacturing costs made the recovery harder. The Vifor acquisition has also disappointed many investors, with questions about whether CSL paid too much and whether the asset can deliver the returns once hoped for.

The vaccine business has added another problem. Lower flu vaccination demand, particularly in the US, has placed pressure on CSL Seqirus and made earnings feel less predictable.

When a company trades on a premium valuation, investors expect reliable growth. CSL has not delivered enough of that in recent years, so the share price has been heavily punished.

Should you buy CSL shares for the next 10 years?

I would still say yes. CSL has clearly lost some of its shine, and investors should not assume the next decade will look like the company’s best years.

But I think the sell-off has created a more attractive starting point.

The company still has global healthcare assets, deep scientific expertise, major plasma infrastructure, and exposure to medical needs that should remain important for many years.

I also think management has a chance to rebuild trust if earnings stabilise, costs improve, and the company proves that Vifor and Seqirus can become stronger contributors.

Foolish takeaway

CSL shares have delivered a modestly positive 10-year return, but the journey has been far from smooth.

The share price is only a fraction higher than it was a decade ago, although dividends lift the total return meaningfully.

The big lesson is that even outstanding companies can disappoint when expectations are too high.

For the next 10 years, I think CSL shares are worth buying on the belief that the business can recover, rebuild confidence, and deliver better growth than investors have seen recently.

The post How have CSL shares performed over 10 years? appeared first on The Motley Fool Australia.

More reading

• What did the market look like 10 years ago? Here’s what’s changed for the ASX 200
• Would Warren Buffett buy CSL shares?
• CSL shares are up 35% since early June. Is the recovery here to stay?
• Where could CSL shares go next? Here’s what brokers are predicting
• How to go from zero to $50,000 with ASX shares

Motley Fool contributor Grace Alvino has positions in CSL. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.